Biblio

Found 56 results
Author Keyword Title Type [ Year(Asc)]
Filters: Keyword is Aged  [Clear All Filters]
2015
A. M. Poveda, Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I. B., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., and Pujade-Lauraine, E., Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial., J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.
R. T. Penson, Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H., and Tewari, K. S., Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)., Lancet Oncol, vol. 16, no. 3, pp. 301-11, 2015.
S. Mahner, Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell'Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., Vergote, I. B., Vasey, P. A., Pujade-Lauraine, E., Gladieff, L., and Ferrero, A., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.
C. Khoon Lee, Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A. - C., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I. B., Scambia, G., Ferrero, A., Harter, P., Pujade-Lauraine, E., and Friedlander, M. Leonard, Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial., Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.
2014
E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial., J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
F. Collinson, Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M. K. B., Ledermann, J. A., Colombo, N., and Swart, A. Marie, Optimal treatment of early-stage ovarian cancer., Ann Oncol, vol. 25, no. 6, pp. 1165-71, 2014.
M. R. Stockler, Hilpert, F., Friedlander, M. Leonard, King, M. Trudy, Wenzel, L. B., Lee, C. Khoon, Joly, F., de Gregorio, N., Arranz, J. Angel, Mirza, M. Raza, Sorio, R., Freudensprung, U., Sneller, V., Hales, G., and Pujade-Lauraine, E., Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer., J Clin Oncol, vol. 32, no. 13, p. 1316, 2014.
T. Sugiyama, Fujiwara, K., Ohashi, Y., Yokota, H., Hatae, M., Ohno, T., Nagai, Y., Mitsuhashi, N., Ochiai, K., and Noda, K., Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study., Ann Oncol, vol. 25, no. 5, pp. 1011-7, 2014.
K. Harano, Terauchi, F., Katsumata, N., Takahashi, F., Yasuda, M., Takakura, S., Takano, M., Yamamoto, Y., and Sugiyama, T., Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: JGOG Trial (JGOG3016)., Ann Oncol, vol. 25, no. 1, pp. 251-7, 2014.
I. B. Vergote, Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C. B., Colombo, N., Lesoin, A., Casado, A., Reinthaller, A., Green, J. A., Buck, M., Ray-Coquard, I., Ferrero, A., Favier, L., Reed, N. Simon, Curé, H., and Pujade-Lauraine, E., Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC GCG, and GCIG study., J Clin Oncol, vol. 32, no. 4, pp. 320-6, 2014.
2013
K. Ushijima, Kamura, T., Tamura, K., Kuzuya, K., Sugiyama, T., Noda, K., and Ochiai, K., Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study., Int J Clin Oncol, vol. 18, no. 1, pp. 126-31, 2013.
F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG., Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.
S. Banerjee, Rustin, G. J. S., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., Gilby, E., Hogg, M., Harper, P., Kipps, E., Lewsley, L. A., Hall, M., Vasey, P. A., and Kaye, S. B., A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG., Ann Oncol, vol. 24, no. 3, p. 687, 2013.
C. Khoon Lee, Simes, R. J., Brown, C., Gebski, V., Pfisterer, J., Swart, A. Marie, Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., Schauer, C., Pisano, C., Parma, G., Baumann, K. H., Ledermann, J. A., Pujade-Lauraine, E., Bentley, J., Kristensen, G. B., Belau, A., Nankivell, M., Canzler, U., Lord, S. J., Kurzeder, C., and Friedlander, M. Leonard, A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer., Ann Oncol, vol. 24, no. 4, p. 943, 2013.
E. Greimel, Kristensen, G. B., van der Burg, M. E. L., Coronado, P., Rustin, G. J. S., del Rio, A. Sanchez, Reed, N. Simon, Nordal, R. R., Coens, C., and Vergote, I. B., Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy., Gynecol Oncol, vol. 131, no. 2, pp. 437-44, 2013.
D. Stark, Nankivell, M., Pujade-Lauraine, E., Kristensen, G. B., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., Velikova, G., Sabate, E., Pfisterer, J., Carey, M. S., Beale, P., Qian, W., Swart, A. Marie, Oza, A. M., and Perren, T. J., Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial., Lancet Oncol, vol. 14, no. 3, p. 243, 2013.
2011
G. Freyer and Tinker, A. V., Clinical trials and treatment of the elderly diagnosed with ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 776-81, 2011.
F. Joly, Ray-Coquard, I., Fabbro, M., Donoghoe, M., Boman, K., Sugimoto, A., Vaughan, M., Reinthaller, A., Vergote, I. B., Ferrandina, G., Dell'Anna, T., Huober, J., and Pujade-Lauraine, E., Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial., Gynecol Oncol, vol. 122, no. 2, p. 232, 2011.
S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial., Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
F. A. Raja, Griffin, C. L., Qian, W., Hirte, H., Parmar, M. K. B., Swart, A. Marie, and Ledermann, J. A., Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer., Br J Cancer, vol. 105, no. 7, pp. 884-9, 2011.
J. - E. Kurtz, Kaminsky, M. C., Floquet, A., Veillard, A. S., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N. Simon, Scambia, G., Varsellona, N., Brown, C., and Pujade-Lauraine, E., Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study., Ann Oncol, vol. 22, no. 11, p. 2423, 2011.

Pages